Search results for "controlled"

showing 10 items of 2729 documents

Herpes Simplex I virus impairs regenerative outcomes of periodontal regenerative therapy in intrabony defects: a pilot study.

2011

Aim To evaluate the impact of herpesvirus type-1 and -2 on the clinical outcomes of periodontal regenerative procedures in isolated deep intrabony pockets, in an experimental population with no detectable periodontal pathogens. Materials and Methods Seventeen periodontal intraosseous defects in 17 moderate-to-advanced periodontitis patients were treated with regenerative therapy and amelogenins. Microbiological evaluation was performed at baseline (after the completion of initial therapy) and at 1 year to exclude the presence of periodontal pathogens. Herpesviruses-1 and -2 DNA were quantified in the pocket tissues associated to the intrabony defect using molecular assays. Clinical attachme…

AdultMaleBone RegenerationCONTROLLED CLINICAL-TRIALHerpesvirus 2 HumanHEALING RESPONSEPopulationAlveolar Bone LossDentistryHerpesvirus 1 HumanACCESS FLAPStatistics NonparametricYoung AdultDental Enamel ProteinsEnamel matrix derivativemedicineAggressive periodontitisHumansPeriodontal PocketGingival RecessionYoung adulteducationBone regenerationGingival recessionGUIDED TISSUE REGENERATIONBONY DEFECTSPeriodontitiseducation.field_of_studybusiness.industryAGGRESSIVE PERIODONTITISMiddle Agedmedicine.diseaseMICROBIOTAHUMAN HERPESVIRUSESPREVALENCEGUIDED TISSUE REGENERATION MINIMALLY INVASIVE SURGICAL TECHNIQUE CONTROLLED CLINICAL-TRIAL AGGRESSIVE PERIODONTITIS HUMAN HERPESVIRUSES HEALING RESPONSE BONY DEFECTS ACCESS FLAP PREVALENCE MICROBIOTAReal-time polymerase chain reactionTreatment OutcomeChronic PeriodontitisDNA ViralGuided Tissue Regeneration PeriodontalPeriodonticsFemaleMINIMALLY INVASIVE SURGICAL TECHNIQUEmedicine.symptombusinessJournal of clinical periodontology
researchProduct

Prospective assessment of post-extraction gingival closure with bone substitute and calcium sulphate

2009

Introduction: The closure of post extraction gingival defects has not been studied in depth, although their achievement is of great importance in certain situations, such as prior to radiotherapy treatment in patients with oral cancer. The aim of this study is to assess the influence of bone substitutes on the time of closure of post extraction gingival defects. Materials and Methods: 22 patients underwent two symmetrical dental extractions. Using a split mouth model, with random assignment to one or other group, one was considered a control group (no filling with any type of material post extraction), whereas the other was considered the experimental group (filling with bone substitute and…

AdultMaleBone substituteAdolescentTooth extractionGingivaDentistrychemistry.chemical_elementCalciumCalcium Sulfatelaw.inventionYoung AdultRandomized controlled triallawMedicineHumansProspective StudiesSplit-mouth study modelClosure (psychology)Prospective cohort studyGeneral DentistryWound HealingBone substitutesbusiness.industryRandom assignmentGingival closureExtraction (chemistry)Middle Aged:CIENCIAS MÉDICAS [UNESCO]OtorhinolaryngologychemistryUNESCO::CIENCIAS MÉDICASBone SubstitutesTooth ExtractionSurgeryFemaleImplantGlassbusiness
researchProduct

Do asthmatic smokers benefit as much as non-smokers on budesonide/formoterol maintenance and reliever therapy? Results of an open label study

2012

SummaryBackgroundStudies with inhaled corticosteroids (ICS) in smoking asthmatics have mostly shown poorer treatment responses than in non-smoking asthmatics.MethodsEuroSMART, an open, randomised, 6-month study, compared budesonide/formoterol (Symbicort ® Turbuhaler®)hhNeither the Symbicort SMART posology nor the dry powder formulation, Turbuhaler, is currently approved in the US. maintenance and reliever therapy (Symbicort SMART®) at two maintenance doses of budesonide/formoterol (160/4.5 μg), 1 × 2 and 2 × 2, in patients with asthma who were symptomatic despite treatment with ICS ± long-acting β2-agonists. The 8424 randomised patients included 886 smokers (11%; aged <40 years or with a sm…

AdultMaleBudesonidePulmonary and Respiratory MedicineSymbicort SMARTmedicine.medical_specialtyPeak Expiratory Flow RatePropensity-matched controlsDrug Administration Schedulelaw.inventionACQ-5Budesonide/formoterol maintenance and reliever therapyPharmacotherapyRandomized controlled triallawFormoterol FumarateSurveys and QuestionnairesInternal medicineAdministration InhalationmedicineHumansAnti-Asthmatic AgentsDosingBudesonideAsthmaSmokersDose-Response Relationship Drugbusiness.industrySmokingmedicine.diseaseAsthmaBronchodilator Agentsrespiratory tract diseasesTreatment OutcomeBudesonide/formoterolEthanolaminesAnesthesiaDisease ProgressionDrug Therapy CombinationFemaleFormoterol FumarateFormoterolbusinessmedicine.drugRespiratory Medicine
researchProduct

Ondasetron versus granisetron in the prevention of chemotherapy‐induced nausea and vomiting. Results of a prospective randomized trial

1994

Background. A single‐institution, prospective, randomized open trial was performed to compare ondansetron and granisetron in the prevention of chemotherapyrelated nausea and vomiting. The effect of antemetic drugs was analyzed indipendently for patients treated with highly emetogenic chemotherapy (Study 1), and those treated with moderately emetogenic regimens (Study 2). Methods. In Study 1. 182 patients treated with chemotherapeutic regimens containing high dose cisplatin (more than 70 mg/m2) were randomized to receive 24 mg of ondasentron intravenously (i. v.) or 3 mg of granisetron i. v. for the control of acute emesis. Patients treated with fractionated chemotherapy and those followed‐u…

AdultMaleCancer ResearchNauseaVomitingmedicine.medical_treatmentAntineoplastic AgentsGranisetronchemotherapyDrug Administration Schedulelaw.inventionOndansetronRandomized controlled triallawmedicineHumansgranisetronProspective StudiesProspective cohort studyAgedChemotherapybusiness.industryMiddle AgednauseamovitingOncologyondansetronAnesthesiaAcute DiseaseVomitingFemalemedicine.symptomCisplatinbusinessmedicine.drugChemotherapy-induced nausea and vomiting
researchProduct

Randomized Multicenter Phase II Trial of Two Different Schedules of Irinotecan Combined with Capecitabine as First-Line Treatment in Metastatic Color…

2004

BACKGROUND The aim of the current randomized Phase II study was to investigate the efficacy and safety of capecitabine combined with irinotecan as first-line treatment in metastatic colorectal carcinoma (CRC). METHODS A total of 140 patients received capecitabine at a dose of 1250 mg/m2 twice daily on Days 2–15 and irinotecan at a dose of either 300 mg/m2 on Day 1 (Arm A) or 150 mg/m2 on Days 1 and 8 (Arm B) every 3 weeks. During the course of the study, enrollment was continued using lower doses of capecitabine (1000 mg/m2 twice daily) and irinotecan (Arm A: 240 mg/m2; Arm B: 120 mg/m2) to improve the safety profile of the combinations. RESULTS Efficacy was evaluable in 134 patients (68 in…

AdultMaleCancer Researchmedicine.medical_specialtyColorectal cancerPhases of clinical researchCOLON CANCERIrinotecanGastroenterologyDeoxycytidineDrug Administration Schedulecolorectal carcinoma first-line treatment irinotecan and capecitabine combination Phase II triallaw.inventionCapecitabineRandomized controlled triallawInternal medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineHumansNeoplasm MetastasisAdverse effectCapecitabineAgedXELIRIbusiness.industryCarcinomaCancerMiddle Agedmedicine.diseaseSurgeryIrinotecanOncologyDrug EvaluationCamptothecinFemaleFluorouracilbusinessColorectal Neoplasmsmedicine.drug
researchProduct

Phase III Randomized Trial of FOLFIRI Versus FOLFOX4 in the Treatment of Advanced Colorectal Cancer: A Multicenter Study of the Gruppo Oncologico Del…

2005

Purpose We performed this phase III study to compare the irinotecan, leucovorin (LV), and fluorouracil (FU) regimen (FOLFIRI) versus the oxaliplatin, LV, and FU regimen (FOLFOX4) in previously untreated patients with advanced colorectal cancer. Patients and Methods A total of 360 chemotherapy-naive patients were randomly assigned to receive, every 2 weeks, either arm A (FOLFIRI: irinotecan 180 mg/m2 on day 1 with LV 100 mg/m2 administered as a 2-hour infusion before FU 400 mg/m2 administered as an intravenous bolus injection, and FU 600 mg/m2 as a 22-hour infusion immediately after FU bolus injection on days 1 and 2 [LV5FU2]) or arm B (FOLFOX4: oxaliplatin 85 mg/m2 on day 1 with LV5FU2 regi…

AdultMaleCancer Researchmedicine.medical_specialtyRandomizationOrganoplatinum CompoundsColorectal cancerfolinic acidatropineplatinum complexLeucovorinGastroenterologylaw.inventionRandomized controlled trialFolfox protocollawInternal medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineHumansInfusions Intravenousirinotecanantineoplastic agentAgedbusiness.industryoxaliplatinMiddle Agedmedicine.diseaseSurvival AnalysisOxaliplatinSurgeryIrinotecanRegimenTreatment OutcomeOncologyFluorouracildrug derivativeDisease ProgressionFOLFIRICamptothecinFemaleFluorouracilIFL protocolColorectal Neoplasmsbusinessmedicine.drugJournal of Clinical Oncology
researchProduct

Neo-adjuvant chemo-(immuno-)therapy of advanced squamous-cell head and neck carcinoma: a multicenter, phase III, randomized study comparing cisplatin…

1998

We carried out an open, randomized, phase III, multicenter clinical trial to compare, in neo-adjuvant setting, the clinical response and toxicity of the combination chemotherapy cisplatin + 5-FU with the same combination plus s.c. recombinant interleukin-2 (rIL-2) in patients with advanced (stage III IV) head and neck squamous-cell carcinoma (HNSCC). Regimen A was the classical Al Sarraf treatment: 100 mg/m2 cisplatin i.v. on day 1 plus 1000 mg m(-2) day(-1) 5-FU on days 1-5 as a continuous infusion. Regimen B was the same as regimen A plus 4.5 MIU/day rIL-2 s.c. on days 8-12 and 15-19. Treatment was repeated every 3 weeks for three cycles. A total of 33 patients were enrolled in the study;…

AdultMaleCancer Researchmedicine.medical_specialtymedicine.medical_treatmentImmunologyAntineoplastic AgentsGastroenterologyGroup Blaw.inventionRandomized controlled triallawInternal medicinemedicineHumansImmunology and AllergyAgedChemotherapybusiness.industryCombination chemotherapyMiddle Agedmedicine.diseaseRecombinant ProteinsSurgeryRegimenOncologyEpidermoid carcinomaHead and Neck NeoplasmsFluorouracilCarcinoma Squamous CellInterleukin-2Drug Therapy CombinationFemaleFluorouracilCisplatinbusinessProgressive diseasemedicine.drugCancer Immunology, Immunotherapy
researchProduct

Pain Neurophysiology Education and Therapeutic Exercise for Patients With Chronic Low Back Pain: A Single-Blind Randomized Controlled Trial.

2018

Abstract: Objective To assess the effect of a pain neurophysiology education (PNE) program plus therapeutic exercise (TE) for patients with chronic low back pain (CLBP). Design Single-blind randomized controlled trial. Setting Private clinic and university. Participants Patients with CLBP for ≥6 months (N=56). Interventions Participants were randomized to receive either a TE program consisting of motor control, stretching, and aerobic exercises (n=28) or the same TE program in addition to a PNE program (n=28), conducted in two 30- to 50-minute sessions in groups of 4 to 6 participants. Main Outcomes Measures The primary outcome was pain intensity rated on the numerical pain rating scale whi…

AdultMaleChronic Pain/rehabilitationmedicine.medical_specialtyEconomicsmedicine.medical_treatmentNeurophysiologyLow Back Pain/rehabilitationPhysical Therapy Sports Therapy and Rehabilitationlaw.invention03 medical and health sciencesDisability Evaluation0302 clinical medicinePhysical medicine and rehabilitationSociologyQuality of lifeRandomized controlled trialPatient Education as TopiclawmedicineAerobic exerciseHumansSingle-Blind Method030212 general & internal medicinePain MeasurementNeurophysiology/educationRehabilitationbusiness.industryMinimal clinically important differenceRehabilitationMiddle AgedLow back painExercise Therapy/methodsExercise TherapyTreatment OutcomeRoland Morris Disability QuestionnairePhysical therapyQuality of LifePain catastrophizingFemaleHuman medicinemedicine.symptomChronic PainbusinessLow Back Pain030217 neurology & neurosurgeryArchives of physical medicine and rehabilitation
researchProduct

Early viral clearance and sustained response in chronic hepatitis C: a controlled trial of interferon and ribavirin after high-dose interferon induct…

2002

High-dose induction with alpha-interferon induces early viral clearance of hepatitis C and combined with ribavirin enhances sustained response. We assess whether adding ribavirin after viral clearance obtained by alpha-interferon induction increased the rate of viral eradication.Forty-one naïve patients with chronic hepatitis C were randomised to receive, after 4 weeks of 10 mU daily of alpha-interferon (induction), 3 mU daily for 22 weeks and 3 mU thrice weekly for 26 weeks of either interferon alone (monotherapy) or interferon plus 1000-1200 mg daily of ribavirin (combination therapy). At the end of the induction phase, 23 (56%) subjects had cleared HCV-RNA. During therapy, breakthrough w…

AdultMaleCombination therapyAdolescentHepacivirusAlpha interferonViremiaEnzyme-Linked Immunosorbent AssayHepacivirusPharmacologyAntiviral AgentsDrug Administration Schedulelaw.inventionchemistry.chemical_compoundRandomized controlled trialInterferonlawVirologyRibavirinHumansMedicineViremiaAgedAntiviral AgentHepatologybiologyDose-Response Relationship Drugbusiness.industryRibavirinvirus diseasesInterferon-alphaHepatitis CHepatitis C ChronicMiddle Agedbiology.organism_classificationmedicine.diseaseInfectious DiseasesTreatment OutcomechemistryRNA ViralDrug Therapy CombinationFemalebusinessmedicine.drugHuman
researchProduct

Osteopathic manual therapy versus conventional conservative therapy in the treatment of temporomandibular disorders: A randomized controlled trial

2010

Summary Objective Temporomandibular disorders (TMD) is a term reflecting chronic, painful, craniofacial conditions usually of unclear etiology with impaired jaw function. The effect of osteopathic manual therapy (OMT) in patients with TMD is largely unknown, and its use in such patients is controversial. Nevertheless, empiric evidence suggests that OMT might be effective in alleviating symptoms. A randomized controlled clinical trial of efficacy was performed to test this hypothesis. Methods We performed a randomized, controlled trial that involved adult patients who had TMD. Patients were randomly divided into two groups: an OMT group (25 patients, 12 males and 13 females, age 40.6±11.03) …

AdultMaleComplementary and Manual Therapymedicine.medical_specialtyPhysical Therapy Sports Therapy and Rehabilitationlaw.inventionRandomized controlled triallawHealth Status IndicatorsHumansMedicineRange of Motion ArticularCraniofacialPain MeasurementAnalysis of Variancebusiness.industryRehabilitationMiddle AgedTemporomandibular Joint DisordersManipulation OsteopathicClinical trialstomatognathic diseasesTreatment OutcomeStomatognathic systemComplementary and alternative medicineEtiologyPhysical therapyFemaleAnalysis of varianceManual therapybusinessRange of motionJournal of Bodywork and Movement Therapies
researchProduct